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Abstract:
Adverse drug reactions are a great cause of concern to the 
medical profession, the patients and the pharmaceutical in-
dustry. However ADR reporting and monitoring is yet to 
catch up in India. Hence we undertook a study to record and 
analyze adverse reactions among all patients admitted to the 
medical wards of a tertiary care. Centre patients admitted to 
all medical wards over one year were assessed for ADRs 
throughout their admission. Suspected ADRs were recorded 
and analyzed for i) the type of reaction ii) severity iii) Con-
sequence on treatment that is if the drug was continued, or 
stopped,   or   needed   to   be   treated   with   other   drugs,   iv) 
Physiological system involved and the v) group of the drugs 
associated with ADRs. Among 1250 patients admitted during 
the study period, 250 adverse events were observed. Majority 
(76.8%) were of mild type, 66% were severe requiring in-
tensive care and 3 patients died. Antimicrobials were re-
sponsible for maximum (42.4%) ADRs followed by drugs 
acting on CNS (20%). When we analyzed the systems af-
fected, CNS side effects were more common in our study. 
While in many other studies Cardiovascular and gastrointest-
inal side effects were the most common. Combination of 
drugs was responsible for a large percentage of ADRs. Inad-
vertent use of antipsychotics with sedatives led to respiratory 
failure in 4 patients of which 1 died. Contaminated IV fluids 
are suspected to be the cause of death in another fatal ADR. 
In conclusion there is a need for vigilant ADR monitoring to 
be done by all doctors to prevent morbidity and mortality 
from ADRs.
Key Words: Adverse drug reactions, Monitoring, Antimicro-
bials, Combination of drugs, Hospital
Introduction:
There is general agreement that drugs prescribed for disease 
are often themselves the cause of a serious amount of disease 
(adverse reactions) ranging from mere inconvenience to per-
manent disability and death. Since drugs are intended to re-
lieve suffering, patients find it particularly offensive that they 
can also cause disease.
It is estimated that adverse reactions cause 2–3 % of con-
sultations in general  practice, upto 3% of admissions to in-
tensive care units and 0.3% of general hospital admissions 
are due to adverse drug reactions (ADR).
1 A recent study 
done in Sweden has implicated ADRs as the 7
th most com-
mon cause of death.
2 Another study involving 19,000 admis-
sions has shown that 6.5% of patient admissions were related 
to an ADR.
3 Data from older studies on ADRs occurring in 
in-patients have suggested that 10-20% of patients experience 
ADRs in hospital.
4-However these studies are decades old 
and with an increase in life expectancy and development in 
medicine over the years, there is a need for more data on the 
ADR in hospital in-patients.
Though ADRs are of great concern to the general public, the 
medical profession, the pharmaceutical industry and the regu-
latory authorities, the concept of ADR reporting is still new 
in India. There are very few centres in India to monitor 
ADRs and hardly any detailed ADR surveys done in India 
are published.
8–12 Hence a study was undertaken to record and 
analyze all adverse reactions among hospitalized patients in 
the medical wards of a tertiary care hospital in Mangalore, a 
South Indian city.
Patients and Methods:
A total of 1250 patients admitted to the medical wards of 
Kasturba Medical College Hospital, Attavar, Mangalore, for 
a period of 1 year were observed for possible ADRs, as per 
W.H.O. definition. W.H.O. has defined ADR as a noxious or 
unintended response to a drug which occurs at doses nor-
mally used in humans for prophylaxis, diagnosis or treatment 
of   a   disease   or   for   modifying   the   physiological   func-
tion.
13 However the term adverse event is now frequently 
used to describe any untoward medical occurrence that may 
be present during treatment with a pharmaceutical product 
but which does not necessarily have a causal relationship 
with the treatment.
14 ADRs were identified by 2 physicians 
and confirmed by a clinical pharmacologist. When there were 
doubts/disagreements, such cases were not included. ADRs 
that occurred outside the hospital and got admitted in our 
hospital were also included. Those who were identified to 
have ADRs were examined and the details recorded in a pro-
forma, where details of the drugs taken, observed reactions, 
measures taken for untoward reactions, investigations and re-
sponse to measures were recorded. 
The results were analyzed under the following headings:
1. Type A or Type B reaction
1
2. Severity
3. Consequence of ADR
4. Types of reactions based on the system involved.
5. Groups of drugs commonly associated with ADR
6. Type of reactions and drugs commonly associated 
with it.
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in everyone if enough of the drug is given because they are 
due to excess of normal, predictable, dose related pharmaco-
dynamic effects of a drug.
Type B or bizarre reactions are those that are not part of 
normal pharmacology of the drug, are not dose related and 
care due to unusual attributes of the patient interacting with 
the drug. The class includes idiosyncrasies and immunologic-
al processes and amount for most fatalities.
2. Severity of ADR – Mild adverse reactions were defined as 
those which did not by itself require prolongation of hospital-
ization and could be managed by simple measures, moderate 
were those ADRs which needed prolongation of hospital stay 
of the patient for treatment of the same and severe were life 
threatening ADRs.
3. Consequences of ADRs were recorded under the follow-
ing headings -
1. The patient continued the drug
2. The dose had to be reduced
3. The drug had to be stopped/withdrawn
4. Another or more drugs were needed to treat an ad-
verse event.
4. Systems involved – Reactions were classified according to 
the system involved i.e., percentage of involvement of differ-
ent systems. Eg. Cardiovascular system, central nervous sys-
tem
5. Group of the offending drug – Drugs were classified ac-
cording to groups and frequency of ADRs noted in each 
group.
6. Details of types of reactions – Type of reaction noted and 
the drugs commonly associated with the same were also re-
corded.
Results:
A total of 250 adverse events were observed and recorded 
during the study period.
Type of adverse event – Table 1 shows the Types of reac-
tions
Table 1: Analysis Of Adverse Reactions
Category No Percentage
Type A (Augmented reac-
tions) 
80 32%
Type B (Bizarre reactions) 170 68%
Total 250 100%
Severity (Table 2): We found a large fraction of ADRs 
(76.8%) to be of mild type while 17.2% of the reactions were 
of moderate type requiring prolongation of hospital stay of 
the patient for the treatment of the event. Six percent of the 
reactions were severe requiring intensive care and 3 patients 
(1.2%) died as a consequence of these events. Details of 
moderate and severe reactions are mentioned in Table 3 and 
4 respectively.
Table 2: Analysis Of Adverse Reactions Based On The 
Severity
ADE Severity No Percentage
Mild 192 76.8%
Moderate 43 17.2%
Severe
Those requiring intensive care 12 4.8%
Death due to ADR 3 1.2%
Total 250 100%
Table 3: Moderate Reactions That Needed Prolonged 
Hospitalization
Types of reaction Offending drug Number
I Neurological
a. Extrapyramidal re-
actions
Haloperidol 2
Chloroquine + metoclopr-
amide*
4
b. Convulsions
Prochlorperazine 1
Chloroquine 3
c. Psychosis
Lithium 1
Theophylline*+ ciprofloxa-
cin
1
Lignocaine IV 1
Chloroquine 4
Corticosteroids 1
Levodopa* + trihexiphen-
idyl
2
Ranitidine 1
Ciprofloxacin 2
Total 23
II Cardio vascular
a. AV Block Quinine 1
b. Q-Tc prolongation Quinine 1
c. Ventricular bigem-
ini
Digoxin 1
d. Multiple ectopics Theophylline*+ salbutamol 3
e. Unstable angina Pentoxyphylline 1
Total 7
III Gastro intestinal
a. GI Haemorrhage
Aspirin * + ibuprofen* 1
Aspirin 2
b. Toxic hepatitis INH * + rifampicin*+ 
pyrazinamide*
3
IV Dermatological
Exfoliative dermatitis Phenytoin 2
V Respiratory
Pulmonary tuberculos-
is
Long term corticosteroids 1
VI Endocrine
Hypoglycemia
Sulphonylurea 2
Quinine 1
Severe HyperglycemiaLong term corticosteroids 1
Gynacomastia Spironolactone 2
* probable offending drug
Table 4: Analysis Of Severe Reactions (Life Threatening)
Types of reaction Offending drugs Number
Haematological
Aplasia
Carbamazepine 1
Busulphan 1
Massive haemorrhage
Warfarin * + ibuprofen 1
Prednisolone * + diclofen-
ac*
1
Respiratory  failure
Haloperidol + lorazepam* 1
Diazepam 2
Haloperidol + diazepam* 1
Acute Renal Failure
Gentamicin 1
Naproxen 1
Acute Pancreatitis Etoposide 1
Cardiac arrhythmias
Theophylline* + norfloxacin 1
Theophylline* + salbutamol 1
Angioneurotic oed-
ema
Diclofenac 1
Anaphylaxis Contaminated IV fluid 1
Stevens Johnson syn-
drome
Sulfonamide, Haloperidol  + 
lorazepam 1
  Total 16
* probable offending drug
2Details of ADR death:
Case 1: Elderly female of 70 years was prescribed corticost-
eroids for radiation pneumonitis which she developed follow-
ing treatment of carcinoma breast. She was initially given a 
high dose of 60 mg/day prednisolone which was tapered to a 
maintenance dose of 10 mg/day. She developed acute abdom-
inal pain and relatives gave diclofenac 1 tab thrice a day on 
day 1 and 2 tablets thrice a day on day 2. She died of massive 
upper gastrointestinal haemorrhage.
Case 2: A young girl (18 yrs) was admitted for ibuprofen (for 
chondritis costo) induced gastritis and persistent vomiting. 
Intravenous fluids were started, and the patient developed 
stridor, hypotension and suddenly died. Autopsy did not re-
veal any other cause of death. Presumed cause of death was 
intravenous fluid induced anaphylaxis, as same batch of flu-
ids was found to be contaminated with fungi.
Case 3: An elderly male of 70 with COPD developed rest-
lessness and hallucinations following intravenous ciprofloxa-
cin for lower respiratory infection. He was sedated with 
diazepam (10 mg). The patient developed severe type II res-
piratory failure.
Consequence of ADR: Table 5 shows the effect of ADR on 
the treatment of the primary disease.
Table 5: Consequence of ADR on The Treatment of 
Primary Disease
Consequence No. Percentage
Patient continued the drug 62 24.8%
Dose had to be reduced 56 22.4%
Drug had to be stopped 122 48.8%
ADR developed after stopping the drug 10 4.0
Total 250 100%
ADR needed treatment with other 
drugs
75 30%
Classes of drugs: When we analyzed the classes of drugs re-
sponsible for adverse events in the order of their frequency, 
we found that antimicrobial agents including antimalarials 
were the drugs which caused maximum number of adverse 
effects (Table 6). Anticancer drug related effects were only 
4% because we have a separate unit for treatment of cancers. 
Among the hormones, most frequent offending agents were 
corticosteroids.
Table 6: Adverse Events According to Class of Drug In-
volved
Drug class No of 
events
Weighted Percent-
age
Antimicrobial agents 106 42.4%
Antimalarials 70  
Antibiotics 23  
Antitubercular drugs 13  
Drugs acting on central 
nervous system 50 20%
Antipsychotics 18  
Analgesics 14  
Antiseizure 8  
Sedatives 7  
Antiparkinsonian 3  
Hormones 31 12.4%
Corticosteroids 24  
Other hormones 7  
Cardiovascular drugs 20 8%
Antihypertensives 13  
Antianginal 5  
Antiarrhythmics 1  
Digoxin 1  
Others
Respiratory system 18 7.2%
Diuretics 7 2.8%
Water for injection 6 2.4%
Anticancer drugs 4 1.6%
Anticoagulants 4 1.6%
Miscellaneous 4 1.6%
Total 250 100%
Systems involved: Table 7 shows the systems affected and 
the number of patients affected. Table 8 shows the type of re-
action under each system and the offending drugs that were 
associated with the same.
3Table 8: System wise Classification Of 250 ADRs With The Possible Offending Drugs
I Central Nervous System
a) Headache  Nitrates, chloroquine
b) Insomnia  Chloroquine, trihexyphenidyl, prednisolone
c) Psychosis  Chloroquine, levodopa, trihexyphenidyl, prednisolone, ranitidine, ciprofloxacin & methyldopa
d) Depression  Chloroquine, reserpine & methyldopa
e) Convulsions  Chloroquine, levodopa, lignocaine, theophylline
f) Respiratory depression  Diazepam, chloropromazine, haloperidol, lorazepam
g) Ptosis  Diazepam
h) Dysarthria  Diazepam, chloropromazine
i) Extrapyramidal Reactions  Chloroquine, metoclopromide, haloperidol, chloropromazine
j) Ataxia, nystagmus  Carbanazepine
k) tingling, numbness  Enalapril
II Cardiovascular System
a. Angina Pentoxyphylline
b. Arrhythmias Digoxin, theophylline, salbutamol, quinine, chloroquine
c. AV block Quinine
d. Oedema Nifedipine, prednisolone
e. Hypotension Enalapril
f. Hypertension  Corticosteroids
III Gastro – intestinal system
a. Gastro intestinal haemorrhage Aspirin, dicofenac, ibuprofen, warfarin, prednisolone
b. Nausea, Vomiting, dyspepsia Cotrimoxazole, erythromycin, pyrazinamide, Chloroquine, griseofulvin, rifampicin, ramipril, theo-
phylline, diclofenac, prednisolone
c) Hepatitis INH, rifampicin, pyrazinamide, ticlopidine
d) Acute Pancreatitis Etoposide
e) Diarrhoea Amoxycilline, warfarin
f) Loss of appetite Tinidazole
g) Dry mouth Imipramine
h) Gingival hyperplasia Phenytoin
i) Oral ulcers Diclofenac
IV Renal  
a. Dysuria Trihexyphenidyl
b. Nephropathy Diclofenac, gentamicin
c. Incontinence & Polyuria Lithium
V Dermatological
a) Pruritus
 Erythromycin, spironolactone, Ampicillin, Ibuprofen, Ciprofloxacin, vitamin injection, phen-
olphthalein, salbutamol,cotrimoxazole, metronidazole, INH, rifampicin, nifedipine, insulin, cloxacil-
lin, Chloroquine, doxycycline, theophylline
b) Rashes Erythromycin, Ibuprofen, Ampicillin, paracetamol, Ciprofloxacin, theophylline, ozothine, 
Chloroquine, primaquine, cotrimoxazole
c) Pigmentation Busulphan
d) Acne Prednisolone
e) Erythema Multiformae Sulpha, Haloperidol, Chlorpromazine, Lithium, carbanazepine
f) Exfoliative dermatitis Phenytoin, Phenobarbitone, Doxycycline, Sulpha
VI Haematological
Pancytopenia Busulphan, carbanazepine
Petechiae & purpura Rifampicin, Prednisolone
VII Musculoskeletal System
a. Cramps Triamterene, Thiazides, Chloroquine
b. Myopathy Corticosteroids, chloroquine
c) Arthralgia Pyrazinamide
d) Muscle tremors Salbutamol, theophylline
VII Multisystem involvement
a. Anaphylaxis Penicillin, Ozothine, Intravenous fluid
b. Angio – oedema Ciprofloxacin, metronidazole
c. Febrile reactions Water for injection
4Previously unreported ADRs
1. Etoposide induced pancreatitis: An adult male (35 yrs) 
suffering from seminoma testis was treated with etoposide as 
part of a multidrug regimen. With the first dose of etoposide, 
patient developed acute pancreatitis. Etoposide was stopped 
and the patient recovered. But, etoposide was repeated as part 
of the regimen following which pancreatitis developed again. 
This established the cause - effect relationship beyond reas-
onable doubt as ‘definite’ (rechallenge). The drug was never 
repeated in the patient. The case has been reported
15.
2. IV fluids induced anaphylaxis: Though reactions to intra-
venous fluids have been mentioned in the literature, to the 
best of our knowledge, no cases of intravenous fluid induced 
anaphylaxis have been reported. The current practices of us-
ing delicate containers make them more susceptible to dam-
age and lead to contamination. A case has been described 
above.
Discussion:
Adverse drug reactions are a common occurrence, but are of-
ten not recognized. Even if they are recognized they are un-
der-reported as many physicians are unaware that clinically 
important ADRs should be reported to ADRs monitoring 
centres. In our series of 1250 hospitalized patients we found a 
high incidence of ADR 16.66% of which 1.2% were fatal 
ADRs. In a meta analysis of all prospective studies of ADRs 
in US hospitals
16 by Lazarou et al an overall incidence of 
15.1% ADR was detected of which 6.7% were serious ADRs 
with a fatal ADR incidence of 0.32%. Our results are com-
parable.
The majority of our reactions were Type B reactions (68%) 
which indicate that most of our reactions were inevitable and 
unavoidable in contrast to the meta analysis by Lazarou et 
al
16, where 76.2% were Type A reactions. The cause for this 
discrepancy may be due to inclusion of large number of reac-
tions to antimalarials and other antimicrobials (42.4%) in our 
set up.
Majority of our patients had mild reactions while 23.2% of 
cases had moderate to severe reactions of which 6% had seri-
ous reactions and of them 1.2% were fatal. Various other 
studies have quoted an incidence of serious ADRs to be 0 - 
20% with a fatality rate of 0 – 0.8%. Table 9 shows various 
studies of ADRs on the incidence and severity and their com-
parison with the present study. A pilot study of 125 in-pa-
tients done in UK showed that 19% of patients suffered from 
ADRs with patients spending 6.5 days longer in hospital than 
those without ADRs.
17 However many of the studies have in-
cluded only patients admitted to the hospitals for ADR or pa-
tients who developed ADR after admission to the hospital. 
Our study has included both the groups.
It is interesting to note that 30% of ADRs had to be treated 
with another drug adding to the cost of therapy and prolong-
ing hospitalization. Cassen et al
18 have proved in a study that 
attributable lengths of stay and costs of hospitalization for 
ADRs are substantial and they have also concluded that it is 
responsible for 2 fold increased risk of death. Bates et al
19 in 
an article have estimated that the annual costs attributable to 
all ADE for a 700 bed teaching hospital is 5.6 million dollars.
Regarding class of drugs associated with ADRs antimicrobi-
als rank high in the list as they are the most commonly pre-
scribed drugs in our set up. Similar observation was noted in 
an Indian study.
2 In a study by Caranasos
20 et al, antimicrobi-
als were the second most common cause of ADRs while non 
– narcotic analgesics topped the list. Kanjanarat et al
21 noted 
cardiovascular drugs to be causative in 17.9% of ADRs while 
Lakshmanan et al
22 in a study of hospital admissions due to 
iatrogenic illness, found antihypertensives to be responsible 
for most of the iatrogenic admissions. However the latter 
study included moderate to severe reactions only and our 
study has included mild side effects also. Steel et al
23 also 
have found low percentage of antibiotic related iatrogenic ill-
ness. Bates et al
24 in a study of 247 patients found 30% of 
ADRs to be due to analgesics, 24% due to antibiotics, 8% 
due to sedatives and 7% due to antineoplastic drugs. Davies 
et al in UK
25, have found the most frequent ADR causative 
drugs relative to usage to be opioid analgesics, anticoagu-
lants, fibriolytics, systemic glucocorticoids, diuretics and an-
tibiotics. However, these differences seen in different places 
could also be due to the variation in drug usage and disease 
prevalence in different places.
Table 9: Comparative Studies on ADRs in Patients While 
in Hospital
Authors Study 
size
Incidence of ADRs %
All 
severit-
ies
Serious Fatal
Davies et al 2009 3322 15.8 15.2 0.4
Bates et al 1995 379 5.3 0.8 0
Bates et al 1995 4031 4.4 1.5 0 – 0.8
Bates et al 1993 420 3.6 1.9 0
Steel at al 1981 815 14.8 2.8 -
Mitchell et al 1979 1669 16.8 - -
Our series 1250 20 0.96 0.24
When we analyzed the systems affected most of them were 
CNS side effects (23.1%) which is much lower than 77.2% 
reported in a systematic review of ADRs by Thomsen et 
al
.26 This is in contrast to previous studies where gastrointest-
inal side effects were more frequent as in the study by Natalie 
et al.
27 However they too noted that neuromuscular problem 
was quite frequent with an incidence of 22.6% whereas  
Caranasos
20 et al found 22.2% cardiovascular ADRs and 
18.5% gastrointestinal ADRs with only 11.1% neurologic  
ADRs in a study of 189 ADRs. This discrepancy may be due 
to inclusion of large number of antimalarials which produced 
CNS side effects.
Among moderate to severe reactions, combinations of drugs 
(drug interactions) were responsible for a large percentage of 
ADRs. 41.1% of ADRs in severe reactions, 29% of cases in 
moderate reactions and 66.6% of fatal reactions were all due 
to combination of drugs. One important observation was that 
of inadvertent use of antipsychotics and sedatives for patients 
with respiratory failure in 4 cases of which one died. As pa-
tients with respiratory failure may present with psychotic 
symptoms one should be careful about sedating a patient with 
preexisting respiratory failure. Drug-drug interactions were 
linked to 59% of ADRs in a study by Davies et al.
25Polyphar-
macy was implicated by them to be the cause in a large per-
centage of cases where incidence of ADR was higher in pa-
tients receiving higher number of drugs compared to those re-
ceiving fewer drugs.
It is important to note that commonly used drugs such as 
chloroquin can produce serious neuropsychiatric problems 
such as extrapyramidal reactions, convulsions and psychosis 
as seen in 11 of our patients. If this fact is not considered, 
these patients may end up with unnecessary investigations 
such as lumbar puncture, EEG and a CT scan.
Our study has included reactions to water for injections and 
IV fluids. Although it cannot be considered as a true ADR, it 
can be considered as an adverse drug event. Intravenous flu-
ids have been associated with reactions such as rigors and 
rarely anaphylaxis. In one of our fatal cases this is suspected, 
because an IV fluid bottle of the same company was found to 
have overt fungal growth in a few bottles.
5We   also   found   a   case   of   etoposide   induced   pancreat-
itis
15 which was unknown previously.
In conclusion, ADR monitoring has to be carried out by all 
the doctors, as the pattern of ADR may vary from place to 
place and time to time. By early recognition of these reac-
tions, necessary action can be taken to prevent mortality and 
morbidity from such reactions.
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